Apyx Medical Corporation (APYX)

From the record

Apyx Medical Corporation's filings since 2017 show 7 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2018-12-12); a warning not to rely on past financial statements (8-K item 4.02, 2 times, the latest 2020-03-19); an auditor change (8-K item 4.01, 2 times, the latest 2020-08-21); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2020-03-16) (its current reports).

From the record

Apyx Medical Corporation's 9 filed years say what it did: revenue went from $10 million in fiscal 2017 to $53 million in fiscal 2025, up 22.8% a year; it rose in 5 of 8 years; the deepest fall was 8% from fiscal 2021 to fiscal 2022; net income was positive in 1 of 9 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Apyx Medical Corporation lost about 77 cents for every dollar of shareholders' money, and gross profitability: its products earned about 49 cents per dollar of everything the company owns. Leverage: it owed about 78 cents per dollar of assets, and net share issuance: its share count grew 15.6% over the year (the filed statements).

From the record

Apyx Medical Corporation's standing among 109 graded names in its industry family: revenue of $53 million in fiscal 2025 ranks in the bottom 43% by size; a net margin of -21.2% ranks in the top 50%; revenue growth of 5.9% a year over the last 3 filed years ranks in the bottom 34% (its annual reports).

From the record

Apyx Medical Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Goodwin, Charles D. II (Chief Executive Officer, as filed), filing under that title since 2018-01-03, 8.9 years (top 27% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 6.2 years (top 36%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (bottom 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Apyx Medical Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $32 million against debt of $35 million leaves -4.7% of its assets as net cash, bottom 32% of its family; cash from operations less capital spending is -17.2% of revenue (bottom 43%); a gross margin of 62.5% (top 46%); research spending of 6.4% of revenue (bottom 28%) (its annual report).

From the record

Apyx Medical Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 5.9% a year over the last three filed years against 22.8% over all 9, slowing (bottom 20% of its family); the newest year grew 9.9% (bottom 41%); research spending grew -9.5% a year (bottom 19%); capital spending grew 3.3% a year (top 46%) (its annual reports). Apyx Medical Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Apyx Medical Corporation's newest year against its own record: revenue of $53 million in fiscal 2025 came in 5.7% above the $50 million its prior three years' pace pointed to (top 21% of its family); net income of $11 million against a prior three-year average of $22 million (top 35%); a net margin of -21.2% against -45.5% before (top 34%) (its annual reports).